Top

Alzheimer's Research & Therapy

Published in:

Open Access 01-08-2014 | Research

Differentially charged isoforms of apolipoprotein E from human blood are potential biomarkers of Alzheimer’s disease

Authors: Oscar Alzate, Cristina Osorio, Robert M DeKroon, Ana Corcimaru, Harsha P Gunawardena

Published in: Alzheimer's Research & Therapy | Issue 4/2014

Abstract

Introduction

Alzheimer’s disease (AD) is the major cause of dementia among the elderly. Finding blood-based biomarkers for disease diagnosis and prognosis is urgently needed.

Methods

We studied protein distributions in brain tissues, cerebrospinal fluid (CSF), and blood of AD patients by using proteomics and a new proteomic method that we call “2D multiplexed Western blot” (2D mxWd). This method allows us to determine in multiple samples the electrophoretic patterns of protein isoforms with different isoelectric points.

Results

Apolipoprotein E (ApoE) displays a unique distribution of electrophoretic isoforms in the presence of AD and also a unique pattern specific to the APOE genotype.

Conclusions

The isoelectric distribution of differentially charged ApoE isoforms was used to determine the presence of AD in a small group of samples. Further studies are needed to validate their use as predictors of disease onset and progression, and as biomarkers for determining the efficacy of therapeutic treatments.

Available only for authorised users

Thies W, Bleiler L: Alzheimer’s disease facts and figures. Alzheimers Dement. 2011, 2011: 208-244.

Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE: Systematic meta-analyses of Alzheimer’s disease genetic association studies: the AlzGene database. Nat Genet. 2007, 39: 17-23. 10.1038/ng1934.CrossRefPubMed

Roses AD: Apolipoprotein E alleles as risk factors in Alzheimer’s disease. Annu Rev Med. 1996, 47: 387-400. 10.1146/annurev.med.47.1.387.CrossRefPubMed

Roses AD: Apolipoprotein E, a gene with complex biological interactions in the aging brain. Neurobiol Dis. 1997, 4: 170-185. 10.1006/nbdi.1997.0161.CrossRefPubMed

Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD: Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer’s disease. Proc Natl Acad Sci U S A. 1993, 90: 1977-1981. 10.1073/pnas.90.5.1977.PubMedCentralCrossRefPubMed

Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD: Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer’s disease. Proc Natl Acad Sci U S A. 1993, 90: 8098-8102. 10.1073/pnas.90.17.8098.PubMedCentralCrossRefPubMed

Thambisetty M, An Y, Tanaka T: Alzheimer’s disease risk genes and the age-at-onset phenotype. Neurobiol Aging. 2013, 34: 2696. e1-5-CrossRefPubMed

Mahley RW: Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988, 240: 622-630. 10.1126/science.3283935.CrossRefPubMed

Mahley RW, Weisgraber KH, Huang Y: Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. Proc Natl Acad Sci U S A. 2006, 103: 5644-5651. 10.1073/pnas.0600549103.PubMedCentralCrossRefPubMed

10.

Blennow K, Vanmechelen E, Hampel H: CSF Total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease. Mol Neurobiol. 2001, 24: 87-97. 10.1385/MN:24:1-3:087.CrossRefPubMed

11.

Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, Hochstrasser DF, Sanchez JC: A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer’s disease. Proteomics. 2003, 3: 1486-1494. 10.1002/pmic.200300470.CrossRefPubMed

12.

Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH: Cerebrospinal fluid proteomic biomarkers for Alzheimer’s disease. Ann Neurol. 2007, 61: 120-129. 10.1002/ana.21038.CrossRefPubMed

13.

Raedler TJ, Wiedemann K: CSF studies in neuropsychiatric disorders. Neuro Endocrinol Lett. 2006, 27: 297-305.PubMed

14.

Zhang J, Goodlett DR, Peskind ER, Quinn JF, Zhou Y, Wang Q, Pan C, Yi E, Eng J, Aebersold RH, Montine TJ: Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging. 2005, 26: 207-227. 10.1016/j.neurobiolaging.2004.03.012.CrossRefPubMed

15.

Zhang J, Goodlett DR, Quinn JF, Peskind E, Kaye JA, Zhou Y, Pan C, Yi E, Eng J, Wang Q, Aebersold RH, Montine TJ: Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer’s disease. J Alzheimers Dis. 2005, 7: 125-133. discussion 173–180PubMed

16.

Zhang J, Montine TJ: Proteomic discovery of CSF biomarkers for Alzheimer’s disease. Ann Neurol. 2007, 61: 497-author reply 497–498CrossRefPubMed

17.

Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T: Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009, 66: 382-389.CrossRefPubMed

18.

Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN: Blood-based protein biomarkers for diagnosis of Alzheimer’s disease. Arch Neurol. 2012, 69: 1318-1325. 10.1001/archneurol.2012.1282.CrossRefPubMed

19.

Osorio C, Sullivan PM, He DN, Mace BE, Ervin JF, Strittmatter WJ, Alzate O: Mortalin is regulated by APOE in hippocampus of AD patients and by human APOE in TR mice. Neurobiol Aging. 2007, 28: 1853-1862. 10.1016/j.neurobiolaging.2006.08.011.CrossRefPubMed

20.

Ervin JF: Banking tissue for neurodegenerative research. Neuroproteomics. Edited by: Alzate O. 2010, Boca Raton, (FL): Frontiers in Neuroscience

21.

DeKroon RM, Osorio C, Robinette JB, Mocanu M, Winnik WM, Alzate O: Simultaneous detection of changes in protein expression and oxidative modification as a function of age and APOE genotype. J Proteome Res. 2011, 10: 1632-1644. 10.1021/pr1009788.CrossRefPubMed

22.

Botero LE, Toro AE, Patino AJ, Salazar G, Rodriguez JC, Suarez-Escudero JC, Alarcon GA, Corcimaru A, Osorio C, Jeong JS, Alzate O: Diabetes mellitus in patients with Alzheimer’s disease: clinical description and correlation with the APOE genotype in a sample population from the province of Antioquia, Colombia. Biomedica. 2012, 32: 239-251.CrossRefPubMed

23.

Wessel D, Flugge UI: A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem. 1984, 138: 141-143. 10.1016/0003-2697(84)90782-6.CrossRefPubMed

24.

Friedman DB, Lilley KS: Optimizing the difference gel electrophoresis (DIGE) technology. Methods Mol Biol. 2008, 428: 93-124. 10.1007/978-1-59745-117-8_6.CrossRefPubMed

25.

Friedman DB: Assessing signal-to-noise in quantitative proteomics: multivariate statistical analysis in DIGE experiments. Methods Mol Biol. 2012, 854: 31-45. 10.1007/978-1-61779-573-2_4.CrossRefPubMed

26.

Winnik WM, Dekroon RM, Jeong JS, Mocanu M, Robinette JB, Osorio C, Dicheva NN, Hamlett E, Alzate O: Analysis of proteins using DIGE and MALDI mass spectrometry. Methods Mol Biol. 2012, 854: 47-66. 10.1007/978-1-61779-573-2_5.CrossRefPubMed

27.

Pinaud R, Osorio C, Alzate O, Jarvis ED: Profiling of experience-regulated proteins in the songbird auditory forebrain using quantitative proteomics. Eur J Neurosci. 2008, 27: 1409-1422. 10.1111/j.1460-9568.2008.06102.x.PubMedCentralCrossRefPubMed

28.

Mascot Database.http://www.matrixscience.com,

29.

Graves DJ, Martin BL, Wang JH: Co- and Post-Translational Modifications of Proteins: Chemical Principles and Biological Effects. 1994, New York: Oxford University Press

30.

Walsh CT, Garneau-Tsodikova S, Gatto GJ: Protein posttranslational modifications: the chemistry of proteome diversifications. Agnew Chem Int Ed Engl. 2005, 44: 7342-7372. 10.1002/anie.200501023.CrossRef

31.

Dekroon RM, Robinette JB, Osorio C, Jeong JS, Hamlett E, Mocanu M, Alzate O: Analysis of protein posttranslational modifications using DIGE-based proteomics. Methods Mol Biol. 2012, 854: 129-143. 10.1007/978-1-61779-573-2_9.CrossRefPubMed

32.

US National Center for Biotechnology Information (NCBI).http://www.ncbi.nlm.nih.gov,

33.

Elias JE, Gygi SP: Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods. 2007, 4: 207-214. 10.1038/nmeth1019.CrossRefPubMed

34.

Hsieh EJ, Hoopmann MR, MacLean B, MacCoss MJ: Comparison of database search strategies for high precursor mass accuracy MS/MS data. J Proteome Res. 2010, 9: 1138-1143. 10.1021/pr900816a.PubMedCentralCrossRefPubMed

35.

Nesvizhskii AI, Keller A, Kolker E, Aebersold R: A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem. 2003, 75: 4646-4658. 10.1021/ac0341261.CrossRefPubMed

36.

Keller A, Nesvizhskii AI, Kolker E, Aebersold R: Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem. 2002, 74: 5383-5392. 10.1021/ac025747h.CrossRefPubMed

37.

Protein Information Resource (PIR).http://pir.georgetown.edu/,

38.

Universal Protein Resource (UniProt).http://www.uniprot.org/,

39.

Cooper B, Feng J, Garrett WM: Relative, label-free protein quantitation: spectral counting error statistics from nine replicate MudPIT samples. J Am Soc Mass Spectrom. 2010, 21: 1534-1546. 10.1016/j.jasms.2010.05.001.CrossRefPubMed

40.

Zhu W, Smith JW, Huang CM: Mass spectrometry-based label-free quantitative proteomics. J Biomed Biotechnol. 2010, 2010: 840518-PubMedCentralPubMed

Title: Differentially charged isoforms of apolipoprotein E from human blood are potential biomarkers of Alzheimer’s disease
Authors: Oscar Alzate
Cristina Osorio
Robert M DeKroon
Ana Corcimaru
Harsha P Gunawardena
Publication date: 01-08-2014
Publisher: BioMed Central
Published in: Alzheimer's Research & Therapy / Issue 4/2014
Electronic ISSN: 1758-9193
DOI: https://doi.org/10.1186/alzrt273

At a glance: The STEP trials

Springer Medicine

Differentially charged isoforms of apolipoprotein E from human blood are potential biomarkers of Alzheimer’s disease

Abstract

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2014

Cerebral inflammation is an underlying mechanism of early death in Alzheimer’s disease: a 13-year cause-specific multivariate mortality study

Basic to translational research in dementia: meeting report from the Alzheimer’s Research UK Conference 2014

The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis

Association of MAPT haplotypes with Alzheimer’s disease risk and MAPT brain gene expression levels

The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial

Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics